Echo IQ is trading 5.47% higher at A$0.68, with no clear company-specific announcement identified for September 24, 2026. - The latest material disclosure remains the September 17 EchoSolv HF FDA update. - It outlined potential appeal, Ombudsman review, or new 510(k) pathways. - The update appears to be background, not a confirmed catalyst for the September 24 move.